{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T05:28:24Z","timestamp":1786512504235,"version":"build-2736575974"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Genetic variants involved in lipid and glucose metabolism have been implicated in liver disease progression and hepatocellular carcinoma (HCC) development in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). However, their prognostic role in patients with established HCC remains unclear. We aimed to investigate the association between MASLD-related genetic variants and overall survival (OS) in patients with MASLD-related HCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We retrospectively evaluated 258 patients with MASLD-related HCC (median age: 73, 49\u201379 years; male sex: 86.8%); most patients had a diagnosis of early tumor (BCLC 0\/A: n = 162; 62.8%).\n                      <jats:italic>PNPLA3<\/jats:italic>\n                      rs738409,\n                      <jats:italic>TM6SF2<\/jats:italic>\n                      rs58542926,\n                      <jats:italic>MBOAT7<\/jats:italic>\n                      rs641738,\n                      <jats:italic>GCKR<\/jats:italic>\n                      rs780094, and\n                      <jats:italic>HSD17B13<\/jats:italic>\n                      rs72613567 variants were genotyped. An independent cohort of viral-related HCC (n = 384) was analysed for exploratory comparison. Overall survival (OS) was evaluated using Kaplan-Meier analysis and multivariable Cox regression.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among the investigated gene variants, only the\n                      <jats:italic>MBOAT7<\/jats:italic>\n                      rs641738 TT genotype was associated with reduced OS in patients with MASLD-related HCC compared to CC\/CT carriers (19.8 vs. 32.2 months; p = 0.006). At multivariable analysis,\n                      <jats:italic>MBOAT7<\/jats:italic>\n                      rs641738 TT genotype retained a nominal association with poorer OS after adjustment for age, sex, tumor burden, and metabolic cofactors (aHR = 1.61, 95% CI 1.05\u20132.46;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.028). Conversely, OS did not differ according to\n                      <jats:italic>MBOAT7<\/jats:italic>\n                      rs641738 genotype in the exploratory viral-related HCC comparison cohort (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.449).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      <jats:italic>MBOAT7<\/jats:italic>\n                      rs641738 genotype was associated with poorer OS in patients with MASLD-related HCC. This finding was not observed in an exploratory viral-related HCC comparison cohort, but between-cohort differences limit etiological interpretation. These results should be considered hypothesis-generating and require external validation.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1931260","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T04:44:54Z","timestamp":1786509894000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["MBOAT7 rs641738 TT genotype is associated with poorer survival in MASLD-related hepatocellular carcinoma"],"prefix":"10.3389","volume":"16","author":[{"given":"Marta","family":"Guariglia","sequence":"first","affiliation":[{"name":"Department of Medical Sciences, University of Torino","place":["Turin, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Paolo","family":"Caviglia","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, University of Torino","place":["Turin, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Gaia","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, Citt\u00e0 della Salute e della Scienza\u2014Molinette Hospital","place":["Turin, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Rosso","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, University of Torino","place":["Turin, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Rolle","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, Citt\u00e0 della Salute e della Scienza\u2014Molinette Hospital","place":["Turin, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Saba","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, University of Torino","place":["Turin, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Dileo","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, University of Torino","place":["Turin, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma Martina","family":"Silvestri","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, University of Torino","place":["Turin, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Armandi","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, University of Torino","place":["Turin, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Carucci","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, Citt\u00e0 della Salute e della Scienza\u2014Molinette Hospital","place":["Turin, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Bugianesi","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, University of Torino","place":["Turin, Italy"]},{"name":"Gastroenterology Unit, Citt\u00e0 della Salute e della Scienza\u2014Molinette Hospital","place":["Turin, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2024.156080","article-title":"An updated overview on hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease: Trends, pathophysiology and risk-based surveillance","volume":"162","author":"Armandi","year":"2025","journal-title":"Metabolism"},{"key":"B2","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/ijc.35097","article-title":"Metabolic dysfunction-associated steatotic liver disease has become the most common cause of hepatocellular carcinoma in Sweden: A nationwide cohort study","volume":"156","author":"Vaz","year":"2025","journal-title":"Int J Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.12.001","article-title":"EASL clinical practice guidelines on the management of hepatocellular carcinoma","volume":"82","year":"2025","journal-title":"J Hepatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/ijc.70092","article-title":"Genetic variants underlying precancerous conditions of hepatocellular carcinoma","volume":"158","author":"Guerrero","year":"2026","journal-title":"Int J Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1002\/ijc.70259","article-title":"The impact of genetic and environmental risk factors on adverse liver outcomes","volume":"158","author":"Zhang","year":"2026","journal-title":"Int J Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.11.024","article-title":"Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores","volume":"74","author":"Bianco","year":"2021","journal-title":"J Hepatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712191","article-title":"A protein-truncating HSD17B13 variant and protection from chronic liver disease","volume":"378","author":"Abul-Husn","year":"2018","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1159\/000539371","article-title":"EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.jhep.2024.01.014","article-title":"Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease","volume":"80","author":"Younossi","year":"2024","journal-title":"J Hepatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII - Renewing consensus in portal hypertension","volume":"76","author":"de Franchis","year":"2022","journal-title":"J Hepatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1016\/j.cgh.2023.04.024","article-title":"Impact of PNPLA3 rs738409 polymorphism on the development of liver-related events in patients with nonalcoholic fatty liver disease","volume":"21","author":"Rosso","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamem.2013.10.003","article-title":"Enrichment of phosphatidylinositols with specific acyl chains","volume":"1838","author":"D\u2019Souza","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1053\/j.gastro.2016.01.032","article-title":"The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent","volume":"150","author":"Mancina","year":"2016","journal-title":"Gastroenterology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.07.045","article-title":"The MBOAT7 variant rs641738 alters hepatic phosphatidylinositols and increases severity of non-alcoholic fatty liver disease in humans","volume":"65","author":"Luukkonen","year":"2016","journal-title":"J Hepatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102658","article-title":"Mboat7 down-regulation by hyper-insulinemia induces fat accumulation in hepatocytes","volume":"52","author":"Meroni","year":"2020","journal-title":"EBioMedicine"},{"key":"B16","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.prostaglandins.2014.08.003","article-title":"Lysophospholipid acyltransferases and eicosanoid biosynthesis in zebrafish myeloid cells","author":"Zarini","year":"2014","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M806194200","article-title":"Lysophospholipid acyltransferases and arachidonate recycling in human neutrophils","volume":"283","author":"Gijon","year":"2008","journal-title":"J Biol Chem"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.734847","article-title":"PNPLA3, TM6SF2, and MBOAT7 influence on nutraceutical therapy response for non-alcoholic fatty liver disease: A randomized controlled trial","volume":"8","author":"Dallio","year":"2021","journal-title":"Front Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"7430","DOI":"10.1038\/s41467-022-35158-9","article-title":"A metabolic associated fatty liver disease risk variant in MBOAT7 regulates toll-like receptor-induced outcomes","volume":"13","author":"Alharthi","year":"2022","journal-title":"Nat Commun"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29064","article-title":"The membrane-bound O-acyltransferase domain-containing 7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B","volume":"65","author":"Thabet","year":"2017","journal-title":"Hepatology"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12757","article-title":"MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C","volume":"7","author":"Thabet","year":"2016","journal-title":"Nat Commun"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102866","article-title":"MBOAT7 down-regulation by genetic and environmental factors predisposes to MAFLD","volume":"57","author":"Meroni","year":"2020","journal-title":"EBioMedicine"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/metabo11030155","article-title":"Insulin resistance across the spectrum of nonalcoholic fatty liver disease","volume":"11","author":"Armandi","year":"2021","journal-title":"Metabolites"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1931260\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T04:44:57Z","timestamp":1786509897000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1931260\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":23,"alternative-id":["10.3389\/fonc.2026.1931260"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1931260","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"article-number":"1931260"}}